Investor Relations

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a preclinical program in Pompe disease. AVROBIO is powered by the plato® gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

Sign up for email alerts

Stock Chart


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations

Our News Latest press releases

Nov 24, 2020

AVROBIO Announces Closing of Underwritten Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock.

Read More

Nov 19, 2020

AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.

Read More

Nov 19, 2020

AVROBIO Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2020-- AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering.

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.